Compartmentalized Accumulation of cAMP near Complexes of Multidrug Resistance Protein 4 (MRP4) and Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Contributes to Drug-induced Diarrhea

C Moon, WQ Zhang, AX Ren, K Arora, C Sinha, S Yarlagadda, K Woodrooffe, JD Schuetz, KR Valasani, Hugo de Jonge, SK Shanmukhappa, MTM Shata, RK Buddington, K Parthasarathi, AP Naren

Research output: Contribution to journalArticleAcademicpeer-review

25 Citations (Scopus)


Diarrhea is one of the most common adverse side effects observed in similar to 7% of individuals consuming Food and Drug Administration (FDA)-approved drugs. The mechanism of how these drugs alter fluid secretion in the gut and induce diarrhea is not clearly understood. Several drugs are either substrates or inhibitors of multidrug resistance protein 4 (MRP4), such as the anti-colon cancer drug irinotecan and an anti-retroviral used to treat HIV infection, 3'-azido-3'-deoxythymidine (AZT). These drugs activate cystic fibrosis transmembrane conductance regulator (CFTR)-mediated fluid secretion by inhibiting MRP4-mediated cAMP efflux. Binding of drugs to MRP4 augments the formation of MRP4-CFTR-containing macromolecular complexes that is mediated via scaffolding protein PDZK1. Importantly, HIV patients on AZT treatment demonstrate augmented MRP4-CFTR complex formation in the colon, which defines a novel paradigm of drug-induced diarrhea.
Original languageUndefined/Unknown
Pages (from-to)11246-11257
Number of pages12
JournalJournal of Biological Chemistry
Issue number18
Publication statusPublished - 2015

Cite this